'Longevi­ty as a ser­vice': In­sil­i­co spins off AI biotech that trains deep learn­ing on an­ti-ag­ing treat­ments

Since its in­cep­tion in 2014, In­sil­i­co has racked up deal af­ter deal on the promise that ar­ti­fi­cial in­tel­li­gence can has­ten drug de­vel­op­ment, tout­ing their work on dis­cov­er­ing small mol­e­cules. The biotech’s founder, Alex Zha­voronkov, has pub­lished sev­er­al sci­en­tif­ic pa­pers quan­ti­fy­ing just how im­pact­ful this tech­nol­o­gy can be.

On Tues­day, Zha­voronkov ex­tend­ed his AI ex­per­tise in­to the field of an­ti-ag­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER